8-K
filed February 28, 2024, 6:59 PM ET
ticker SDGR
CIK 0001490978
earnings
confidence high
sentiment positive
materiality 0.75
Schrödinger Q4 software rev +44% to $68.7M; guides 6-13% software growth in 2024
Schrodinger, Inc.
2023-FY EPS reported
$0.54
revenue$216,666,000
- Q4 software revenue $68.7M (+44% YoY); total revenue $74.1M (+30.4%); net loss $30.7M.
- Full-year 2023 total revenue $216.7M (+19.7%); net income $40.7M vs $149.2M loss in 2022.
- 2024 guidance: software revenue growth 6-13%; drug discovery revenue $30-35M; expects higher cash burn.
- Pipeline: Phase 1 data for MALT1 inhibitor SGR-1505 well tolerated; two clinical programs; Wee1/Myt1 IND expected H1 2024.
- Total ACV grew 9.7% to $154.2M; customers with >$1M ACV rose from 18 to 27.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Schrodinger, Inc. reported year ended December 31, 2023 results: revenue $216.7 million, net income $40.7 million.
- Period
- year ended December 31, 2023
- Revenue
- $216.7 million
- Net income
- $40.7 million
- Result
- reported results
Exact text from the filing
Total revenue for the full year increased 19.7% to $216.7 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Schrodinger, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $74.1 million, net income $30.7 million net loss.
- Period
- fourth quarter and year ended December 31, 2023
- Revenue
- $74.1 million
- Net income
- $30.7 million net loss
- Result
- reported results
Exact text from the filing
Total revenue for the fourth quarter increased 30.4% to $74.1 million
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.